Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Abstract Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-47618-3 |
| _version_ | 1827634853361745920 |
|---|---|
| author | Haruka Miyazaki Namiko Hoshi Tsukasa Ishida Chiharu Nishioka Sachiko Ouchi Daisuke Shirasaka Tomoo Yoshie Yoshinori Munetomo Yoshio Sakamoto Tatsuya Osuga Saori Matsui Toshiki Hyodo Tamami Denda Daisuke Watanabe Makoto Ooi Yuzo Kodama |
| author_facet | Haruka Miyazaki Namiko Hoshi Tsukasa Ishida Chiharu Nishioka Sachiko Ouchi Daisuke Shirasaka Tomoo Yoshie Yoshinori Munetomo Yoshio Sakamoto Tatsuya Osuga Saori Matsui Toshiki Hyodo Tamami Denda Daisuke Watanabe Makoto Ooi Yuzo Kodama |
| author_sort | Haruka Miyazaki |
| collection | DOAJ |
| description | Abstract Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule 1. Reports about histological features that predict vedolizumab efficacy are scarce. So, we examined the association between histological features and vedolizumab efficacy. This was a multicenter, retrospective study of patients with UC treated with vedolizumab. Biopsy specimens taken from the colonic mucosa prior to vedolizumab induction were used, and the areas positively stained for CD4, CD68, and CD45 were calculated. Clinical and histological features were compared between those with and without remission at week 22, and the factors associated with clinical outcomes were identified. We enrolled 42 patients. Patients with a high CD4+ infiltration showed a better response to vedolizumab [odds ratio (OR) = 1.44, P = 0.014]. The concomitant use of corticosteroids and high Mayo scores had a negative association with the vedolizumab response (OR = 0.11, P = 0.008 and OR = 0.50, P = 0.009, respectively). Histological evaluation for CD4+ cell infiltration may be helpful in selecting patients who can benefit from vedolizumab. |
| first_indexed | 2024-03-09T15:20:05Z |
| format | Article |
| id | doaj.art-feac46e1e16e4db6837ec810e6c4879f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-09T15:20:05Z |
| publishDate | 2023-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-feac46e1e16e4db6837ec810e6c4879f2023-11-26T12:54:57ZengNature PortfolioScientific Reports2045-23222023-11-011311910.1038/s41598-023-47618-3Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitisHaruka Miyazaki0Namiko Hoshi1Tsukasa Ishida2Chiharu Nishioka3Sachiko Ouchi4Daisuke Shirasaka5Tomoo Yoshie6Yoshinori Munetomo7Yoshio Sakamoto8Tatsuya Osuga9Saori Matsui10Toshiki Hyodo11Tamami Denda12Daisuke Watanabe13Makoto Ooi14Yuzo Kodama15Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Gastroenterology, Akashi Medical CenterDivision of Gastroenterology, Konan Medical CenterDivision of General Internal Medicine, Hyogo Prefectural Harima-Himeji General Medical CenterDivision of Gastroenterology, Japanese Red Cross Kobe HospitalDivision of Gastroenterology, Kita-Harima Medical CenterDivision of General Surgery, Himeji Central HospitalDivision of Gastroenterology, Hyogo Prefectural Kakogawa Medical CenterDivision of Gastroenterology, Takatsuki General HospitalDivision of Gastroenterology, Yodogawa Christian HospitalDepartment of Diagnostic Pathology, Kobe University Graduate School of MedicineDepartment of Pathology, The Institute of Medical Science Research Hospital, The University of TokyoDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of MedicineAbstract Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule 1. Reports about histological features that predict vedolizumab efficacy are scarce. So, we examined the association between histological features and vedolizumab efficacy. This was a multicenter, retrospective study of patients with UC treated with vedolizumab. Biopsy specimens taken from the colonic mucosa prior to vedolizumab induction were used, and the areas positively stained for CD4, CD68, and CD45 were calculated. Clinical and histological features were compared between those with and without remission at week 22, and the factors associated with clinical outcomes were identified. We enrolled 42 patients. Patients with a high CD4+ infiltration showed a better response to vedolizumab [odds ratio (OR) = 1.44, P = 0.014]. The concomitant use of corticosteroids and high Mayo scores had a negative association with the vedolizumab response (OR = 0.11, P = 0.008 and OR = 0.50, P = 0.009, respectively). Histological evaluation for CD4+ cell infiltration may be helpful in selecting patients who can benefit from vedolizumab.https://doi.org/10.1038/s41598-023-47618-3 |
| spellingShingle | Haruka Miyazaki Namiko Hoshi Tsukasa Ishida Chiharu Nishioka Sachiko Ouchi Daisuke Shirasaka Tomoo Yoshie Yoshinori Munetomo Yoshio Sakamoto Tatsuya Osuga Saori Matsui Toshiki Hyodo Tamami Denda Daisuke Watanabe Makoto Ooi Yuzo Kodama Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis Scientific Reports |
| title | Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis |
| title_full | Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis |
| title_fullStr | Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis |
| title_full_unstemmed | Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis |
| title_short | Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis |
| title_sort | association of cd4 positive cell infiltration with response to vedolizumab in patients with ulcerative colitis |
| url | https://doi.org/10.1038/s41598-023-47618-3 |
| work_keys_str_mv | AT harukamiyazaki associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT namikohoshi associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT tsukasaishida associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT chiharunishioka associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT sachikoouchi associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT daisukeshirasaka associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT tomooyoshie associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT yoshinorimunetomo associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT yoshiosakamoto associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT tatsuyaosuga associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT saorimatsui associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT toshikihyodo associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT tamamidenda associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT daisukewatanabe associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT makotoooi associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis AT yuzokodama associationofcd4positivecellinfiltrationwithresponsetovedolizumabinpatientswithulcerativecolitis |